期刊文献+

马方综合征并发感染性心内膜炎的外科治疗体会

Surgical Treatment Experience of Infective Endocarditis in Marfan Syndrome
原文传递
导出
摘要 目的:探讨马方综合征并发感染性心内膜炎的外科治疗的体会。方法:回顾性分析2009年7月至2012年12月我院30例马方综合征并发感染性心内膜炎患者,男19例,女11例,年龄23-58(41.6±15.2)岁,所有患者均进行了抗生素治疗和心瓣膜置换或成形术,其中对患者进行经典Bentall手术12例,纽扣法Bentall手术18例,比较分析手术治疗马方综合征并发感染性心内膜炎疗效。结果:手术时间276-742(405.0±125.0)min,体外循环时间115-319(159.0±43.0)min,机械通气辅助时间1~12(2.4±2.0)d,住院时间10-60(28.5±11.0)d,术后出现并发症有7例,经二期手术治愈有5例,2例抢救无效死亡,并发症发生率为23.3%,死亡率为6.7%。结论:对于马方综合征并发感染性心内膜炎患者,正确把握手术的时机和抗感染药物治疗剂量,积极采取外科手术治疗是最佳的治疗方法。 Objective: To discuss the Surgical treatment experience of infective endocarditis in Marfan syndrome. Methods: In 2009 July to December 2012, 30 patients with concurrent Malaysia syndrome and infective endocarditis, (19 male and female in 11 cases, aged 23-58 (41.6:1: 15.2) were treated and retrospectively analyze. Bentall surgery on the patients with antibiotic therapy and heart valve replacement or plasty, analysis of surgical treatment for Malaysia syndrome complicated with infective endocarditis were compared and analyzed. Results: Operating time was 276-742 (405.0± 125.0)min; CPBT was 115-319 ( 159.0± 43.0)min; mechanical ventilation as- sist time was 1-12 (2.4± 2.0)d; length of stay was 10-0 (28.5 ± 11.0)d. Seven patients after surgery had complications; patients cured by thesecond surgery were 5 cases, death of rescue were invalid in2 cases. The incidences of complications and mortality were 23.3% and 6.7%, respectively. Coneinsion: For infective endocarditis in Marfan syndrome, taking surgical treatment is the best treatment method with grasping the correctly operation timing and anti-infection drug treatment.
出处 《现代生物医学进展》 CAS 2013年第27期5289-5291,5397,共4页 Progress in Modern Biomedicine
关键词 马方综合征 感染性心内膜炎 外科治疗 Marfan syndrome Infective endocarditis Surgical treatment
  • 相关文献

参考文献20

  • 1Bentall H, de Bono A. A technique for complete replacement of the as- cending aorta[J]. Thorax, 1968, 23 (4): 338-339.
  • 2公兵,杨秀滨.马方综合征血管病变的治疗进展[J].中国胸心血管外科临床杂志,2012,19(6):668-670. 被引量:3
  • 3龚利民,叶晓芳,楊京华,刘双.马方综合征伴呼吸困难分析并文献复习[J].中国医药,2012,7(4):461-463. 被引量:5
  • 4Gott VL, Cameron DE, Alejo DE, et al. Aortic root replacement in 271 Marfan patients:a 24-year experience[J]. Ann Thorac Surg, 2002, 73( 2):438-443.
  • 5Hourl R, Soustelle C, Kirsch M, et al. Long-term results of the Bentall operation versus separate replacement of the ascending aorta and aor- ticvalve[J]. J Heart Valve Dis, 2002, 11(4):485-491.
  • 6Kerendi F, Guyton RA, Vega JD, et al. Early results of valvesparing aortic root replacement in high-risk clinical scenarios[J]. Ann Thorac Surg, 2010, 89(2):471-476.
  • 7沈弛晶,尹元正.糖尿病与牙周炎的相互关系[J].牙体牙髓牙周病学杂志,2007,17(5):292-295. 被引量:25
  • 8Prifti E, Bonacchi M, Frati G, et al. Early and long-term outcome in patients undergoing aortic root replacement with composite gratt ac- cording to the Bentall's technique [J]. Eur J Cardiothorac Surg, 2002, 21(1):15-21.
  • 9Cohn LH, Rizzo R J, Adams DH, ct al. Reduced mortality and morbidity for ascending aortic aneurysm resection regardless of cause [J]. Ann Thorac Surg, 1996, 62(2):463-468.
  • 10Bernhardt AM, Treede H, Rybczynski M, et al. Comparison of aortic root replacement in patients with Marfan syndrome [J]. Eur J Cardio- thorac Surg, 2011, 40(5): 1052-1057.

二级参考文献145

  • 1郝梅,柳洁,原韶钟,雷建华,谢敦祥.牙周非手术治疗对糖尿病患者糖代谢及TNF-α的影响[J].现代口腔医学杂志,2005,19(4):345-348. 被引量:19
  • 2谢春,李幼姬.糖皮质激素和实脾饮加减对肾内源性抗氧化酶的影响及其意义[J].中华肾脏病杂志,1996,12(3):134-137. 被引量:6
  • 3Cohen M, Arjomand H, Pollack CV. The evolution of thrombolytis therapy and adjunctive antithrombotic regimens in acute ST-segmen elevation myocardial infarction [J]. Am J Emerg Med, 2004, 22 (1): 14-23.
  • 4Eikelboom JW, Hirsh J, Weitz J, et al. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction,stroke,or cardio vascular death in patients at high risk for ear di ovascular events[J].Circulation, 2002, 105(2 ): 1650.
  • 5McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides[J]. Rev Cardiovasc Med, 2003, 4(4), 13-19.
  • 6Galvani M, Fetrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes [J]. Eur J Heart Fail, 2004, 6(3): 327-333.
  • 7James SK, Lindahl B, Siegbabn A, et al. N-terminal pro-brain natriurefic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy[J]. Circulation, 2003,108 (3): 275 -281.
  • 8Jolly S, Tan M, Mendelsohn A, et al. Comparison of effectiveness of enoxaparin versus tmfractionated heparin to reduce silent and clinically apparent acute myocardial infarction in patients presenting with non-ST-segment elevation acute coronary syndrome[J]. Am J Cardiol,2007,99(2): 186-188.
  • 9Yusuf S, Shamir R, Bernard J, et al. On behalf of the CURE (Clopidogrel in unstable angina to prevent recurrent e-vents)trial investigators[J]. Circulation, 2003, 107: 966-972.
  • 10Ugo F, Ardissino D. Low-molecular-weight heparins in acute coronary syndrome:acquired results and new perspectives [J]. G Ital Cardiol (Rome), 2006, 7(12):771-779.

共引文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部